Synthesis, structure, spectral, redox properties and anti-cancer activity of Ruthenium(II) Arene complexes with substituted Triazole Ligands

Muley, Arabinda and Karumban, Kalai Selvan and Gupta, Parth and Kumbhakar, Sadananda and Giri, Bishnubasu and Raut, Rajnikant and Misra, Ashish and Maji, Somnath (2021) Synthesis, structure, spectral, redox properties and anti-cancer activity of Ruthenium(II) Arene complexes with substituted Triazole Ligands. Journal of Organometallic Chemistry, 954-95. pp. 1-14. ISSN 0022-328X

Text
Journal_of_Organometallic_Chemistry.pdf - Published Version
Restricted to Registered users only
Download (4MB) | Request a copy

Abstract

Three versatile half-sandwich ruthenium(II) p-cymene complexes bearing substituted triazole ligands exhibit promising cancer cell growth inhibition activity towards A549 lung adenocarcinoma and MDA-MB-231 breast adenocarcinoma cells. In this context, the triazole based phthalimide protected new ligand (2-(3, 5-di(pyridin-2-yl)-4H-1,2,4-triazol-4-yl) isoindoline-1,3-dione) (L1) was prepared. Three ruthenium(II) p-cymene complexes [Ru(η6-p-cymene)(L1)Cl]Cl: [1]Cl, L1: (2-(3,5-di(pyridin-2-yl)-4H-1,2,4-triazol-4-yl)isoindoline-1,3-dione), [Ru(η6-p-cymene)(L2)Cl]Cl: [2]Cl and [Ru(η6-p-cymene)(L2)Cl](PF6): [2](PF6), L2 (2,2′-(4-(1H-pyrrol-1-yl)-4H-1,2,4-triazole-3,5-diyl) dipyridine) have been successfully synthesized and characterized by different spectral and analytical tools. Pyrrole protected substituted ruthenium complexes [2]Cl and [2](PF6) have been successfully identified structurally by single-crystal X-ray diffraction studies and confirmed the successful anion exchange. The redox properties of the ligands and the targeted metal complexes have been carefully examined. Cellular staining, live-cell imaging and MTT assay have been performed for all the complexes. We have demonstrated that our synthesized ruthenium(II) p-cymene complexes are capable of inducing significant cytotoxicity in A549 lung cancer cell lines, with an IC50 values of 6.56 ± 0.31 µM, 4.74 ± 0.2 µM and 13.67 ± 0.64 µM and in MDA-MB-231 breast cancer cell lines with an IC50 values of 1.13 ± 0.046 µM, 0.36 ± 0.016 µM and 11.32 ± 0.49 µM for [1]Cl, [2]Cl and [2](PF6) respectively. © 2021 Elsevier B.V.

[error in script]

IITH Creators:

IITH Creators	ORCiD
Misra, Ashish	https://orcid.org/0000-0002-3042-8302
Maji, Somnath	http://orcid.org/0000-0001-6047-1339

Item Type:

Article

Additional Information:

Financial support received from Science and Engineering Research Board (SERB), Department of Science and Technology, India: project no. ECR/2016/000382 (fellowship to S.K.); Council of Scientific and Industrial Research (CSIR) (fellowship to A.M., K.S., B.G. and R.R.) and Indian Institute of Technology Hyderabad are gratefully acknowledged. P.G. acknowledges fellowship support from Ministry of Education. A.M. acknowledges funding support from DST SERB (ECR/2017/002544) and IIT Hyderabad.

Uncontrolled Keywords:

Anticancer activity; Crystal structures; Electrochemistry; In vitro cytotoxicity; Redox-active ligand; Ruthenium-arene complexes

Subjects:

Chemistry

Divisions:

Department of Biotechnology
Department of Chemistry

Depositing User:

. LibTrainee 2021

Date Deposited:

03 Oct 2022 13:55

Last Modified:

03 Oct 2022 13:55